![](https://investorshub.advfn.com/uicon/75.png?cb=1513767336)
Friday, April 16, 2021 7:15:35 AM
Who is Calalent:
At Catalent, we are keenly aware that every biologic drug has different needs and challenges. That is why we provide comprehensive solutions from development and biomanufacturing to fill/finish and packaging for new biological entities, cell and gene therapies, biosimilars, sterile injectables and antibody-drug conjugates.
As a global biologics leader with state-of-the-art facilities in Europe and North America, we have experience working with customers of all sizes from top global multinational pharma to small and virtual companies. Our advanced technologies including GPEx®, SMARTag®, and adeno-associated virus (AAV) vectors can help you create next generation therapies. Our OneBio® integrated offering leverages Catalent’s Follow the Molecule® development and manufacturing approach to provide you accelerated and integrated solutions from development to supply.
We attract some of the best experts in the industry, and that’s why our employees are committed to driving service excellence and actively contributing to a “Patient-First” culture, putting the patient at the center of everything we do.
Catalent’s commitment to quality can be seen throughout our organization, from our inspection-ready sites to our efforts to continually refine and improve the type and scope of services we can provide our customers. We pride ourselves on our ability to offer our customers biologic development and manufacturing solutions that are innovative and flexible and support them in their pursuit of significant and potentially life-changing and life-saving medications.
To watch a video to see how Catalent can take your biologic to clinic or market, faster go to:
https://biologics.catalent.com/about-us/overview/
Recent PKTX News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/17/2024 07:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 07:13:41 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 05/15/2024 09:14:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 12:46:59 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM